Biotech

0 478
TrovaGene Inc TROV Stock News

TrovaGene Inc (NASDAQ: TROV) is off to an incredible start to the trading session this morning, and for good reason. The company issued a PR informing investors of an agreement that will drive revenue. Of course, this led to excitement among investors, prompting gains in the value of the stock. As is almost always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (10:05), TROV is trading at $1.22 per share after a gain of $0.27 per share or 28.75% thus far today.





TROV Gains On ctDNA Agreement

As mentioned above, TrovaGene is having an incredibly strong day in the market thus far today following the issuance of a press release. In the release, investors learned that the company has entered into an agreement with a worldwide, premier biopharmaceutical company. Under the agreement, TROV will provide Trovera® urine circulating tumor DNA (ctDNA) biomarker tests and services.

As a result of this agreement, TROV will be providing urine and blood biopsy tests. These tests will be used to assess and monitor mutation status in clinical trials of potential first-in-class or best-in-class oncology therapeutics that are currently under development. In a statement, Bill Welch, CEO at TROV, had the following to offer…




We’re pleased to have our liquid biopsy tests included in the clinical trials with a leading biopharmaceutical company and to participate in their development of transformative therapies to improve the lives of cancer patients worldwide… This agreement follows a separate, recent announcement of our collaboration with AstraZeneca and demonstrates the value of our Trovera® biomarker technology.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TROV. In particular, we’re interested in following the company through the ongoing work surrounding the Trovera® biomarker tests. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 481
DarioHealth DRIO Stock News

DarioHealth Corp (NASDAQ: DRIO) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced increased coverage with regard to providers in the diabetes industry. With such positive news, investors excitedly have been pushing the stock upward throughout the morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:19), DRIO is trading at $2.19 per share after a gain of $0.06 per share or 2.66% thus far today.





DRIO Gains On Coverage News

As mentioned above, DarioHealth is having a strong day in the market today after announcing expanded insurance coverage. The company said that it would be expanding its insurance coverage provider network across the United States with additional service providers that will be able to target up to 10 million customers with diabetes. In a statement, Erez Rphael, Chairman and CEO at DRIO, had the following to offer…




Our goal is to deliver the Dario(TM) Blood Glucose Monitoring System into as many hands of those who need it, and with the additional insurance coverage option, we expect to have the capabilities to cover up to 30% of consumers in the U.S. diabetes market.

In just a few months since launching our insurance health coverage initiative, we have received tremendous feedback and we are able to offer insurance reimbursement from companies such as Aetna, United HealthCare, and various Blue Cross Blue Shield organizations. As such, we have signed on additional partners to increase our U.S. market penetration.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DRIO. In particular, we’re interested in following the ongoing work with regard to the company’s insurance initiative and excited to continue seeing positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 2052
Bristol-Myers Squibb Co BMY Stock News

Bristol-Myers Squibb Co (NYSE: BMY) is is experiencing a relatively strong spike in the market at the moment, and for good reason. There are rumors surfacing that the company will soon be taken over. Of course, these rumors are leading to excitement among investors, sending the stock upward. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:45), BMY is trading at $55.88 per share after a gain of $0.22 per share (0.40%) thus far today.





Rumors Suggest That PFE May Buy BMY

As mentioned above, the spike that BMY is seeing in the market at the moment has to do with the idea that the company will soon be taken over. Currently, rumors are breaking all over the social space that Pfizer Inc. (NYSE: PFE) is interested in taking the company over. However, there is no indication at what price, nor confirmation from either side at the moment.




It’s important to remember that rumors like this are common in the market. In fact, there was a rumor just a few months ago that PFE was interested in taking BMY over, but the rumor never came to fruition. With that said, it is unlikely that this takeover is going to happen. So, if you’re going to trade on this news, please do so with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both BMY and PFE. In particular, we’re interested in following the story surrounding the potential takeover. While it is unlikely that the rumor is correct, if it is, the takeover would likely generate an incredible return of value for investors. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1204
ACADIA Pharmaceuticals ACAD Stock News

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having a strong start to the trading session this morning after rumors broke surrounding the company. The rumors led to excitement which sent the stock toward the sky, prompting our partners at Trade Ideas to alert us to the gains. At the moment (10:30), ACAD is trading at $29.49 per share after a gain of $1.27 per share (4.50%) thus far today.





ACAD Gains On Takeover Rumor

As mentioned above, ACADIA is having a wonderful start to the trading session this morning as rumors circle social media. The rumor is that the company will soon be taken over. This is something that we’ve seen often surrounding ACAD recently. The rumor today doesn’t suggest who the buyer might be nor at what price. In fact, it’s overwhelmingly vague.




When trading on this type of news, it’s important to keep in mind that rumors are nothing new to the market. In fact, they happen all the time, with very few of them proving to be true. In this particular case, we believe the rumor lacks validity. First and foremost, this is about as vague as vague market rumors get. On top of that, we’ve seen a few rumors surrounding ACAD recently, none of them proving to be true. So, if you’re going to try and turn a profitable trade off of this move, please make sure to move with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ACAD. In particular, we’re interested in following the rumors surrounding the potential takeover. While we don’t believe that these rumors are true, anything could happen in the market, and a takeover would yield incredible value for shareholders. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 10833
Delcath Systems, Inc. DCTH Stock News

Delcath Systems, Inc. (NASDAQ: DCTH) is having yet another incredible day in the market today. Investors seem to be putting full faith and support in the CEO of the company and his driving effort to turn things around. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:09), DCTH is trading at $0.18 per share after a gain of $0.08 per share (80.71%) thus far today.





DCTH Is Having Yet Another Exceptional Day In The Market

Delcath has been running upward in the market for the past several trading sessions, and for good reason. Investors are putting their full support into Jennifer Simpson, the CEO of the company that is striving for excellence.




At the moment, the key for Simpson, and the investors that are backing her, is getting the stock to $1 per share before it is delisted from the NASDAQ. Of course, with the stock trading at $0.18 per share, that’s a tall order. In fact, a reverse split was proposed to investors to push the stock to that direction. However, the company didn’t receive the votes it needed for the split.

Nonetheless, the bulls believe that delisting isn’t going to be an issue. In fact, if you take a look at StockTwits at the moment. You’ll see several bulls saying that the stock will hit $1 by Friday.

So, What’s The Value Proposition Here?

The answer to the question above is a relatively simple one. Ultimately, the value proposition is the company’s proprietary Hepatic Delivery System. Currently, the company is working on a Phase 2 clinical trial evaluating the combination of Melphalan with the Hepatic Delivery System for the treatment of both liver cancer and bile duct cancer. There’s also a Phase 3 clinical trial in which DCTH is investigating Melphalan Hydrochloride for injection for use with the Hepatic Delivery System in patients with Hepatic Dominant Ocular Melanoma.

The True Value Is A Potential Acquisition

At the end of the day, the oncology space is an incredibly competitive one. One where acquisitions happen all the time in order to maintain or increase dominance. Well, DCTH is likely a perfect takeover target. Even after the strong run we’ve seen on the stock as of late, the market cap remains relatively low at just $64 million. That’s pennies in the oncology space, and with multiple clinical trials, there’s no reason that a larger player wouldn’t be willing to put up some change for the company. Of course, doing so quickly would allow the larger player to get a hefty discount!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DCTH. In particular, we’ll be following the company closely to see what CEO Jennifer Simpson pulls out of her hat to bring the stock to $1 per share. In the longer term, we’re interested in following the ongoing clinical trials and watching for a takeover offer, as with the value proposition offered here, it’s likely not a matter of if, but a matter of when. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 515
Navidea Biopharmaceuticals NAVB Stock News

Navidea Biopharmaceuticals Inc (NYSEMKT: NAVB) is off to an incredible run in the market as we speak, and for good reason. Minutes ago, the company issued a press release surrounding a distribution agreement. Of course, this led to excitement among investors, sending the stock upward and prompting an alert from our partners at Trade Ideas. At the moment, NAVB is trading at $0.59 per share after a gain of $0.07 per share or 14.04% thus far today.





NAVB Announces Distribution Agreement

As mentioned above, Navidea Biopharmaceuticals is having a strong time in the market at the moment after issuing a press release informing investors of an exclusive license and distribution agreement. The agreement was signed with Sayre Therapeutics and surrounds the development and commercialization of Tc 99m tilmanocept in India.




According to the agreement, Sayre Therapeutics will be making an upfront payment to NAVB. Following the upfront payment, Navidea will be eligible to receive milestone payments as well as double-digit royalties associated with the sale of Tc 99m tilmanocept in India. The exact amount of the upfront payment, milestone payments, and royalties have not yet been offered to the investing public. In a statement, Michael Goldberg, M.D., President and CEO at NAVB, had the following to offer…

We view this partnership as an important milestone in the expansion of tilmanocept’s adoption globally and reiterates our commitment to patients the world over. The terms of our agreement with Sayre are favorable and the increased economics will drive further revenues to fund our other pipeline assets.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NAVB. In particular, we’re interested in following the news surrounding the agreement highlighted above as well as following the company through ongoing work with regard to its robust pipeline. Nonetheless, we’ll continue to follow the news closely and bring the story to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 2341
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ: CYTR) is off to an interesting day in the market this morning. We’re still early on, but the stock has already seen both red and green and continues to fluctuate. Nonetheless, now may be the perfect time to get involved. At the moment (10:13), CYTR is trading at $0.68 per share after a gain of $0.01 per share (1.27%) thus far today.





Dr. Shanta Chawla Could Change The Game

Early this morning, an 8K was filed with regard to the recent promotion of Dr. Shanta Chawla. The promotion will put Chawla in a leadership position with regard to Drug Development. In fact, he is taking on the role of Senior Vice President of Drug Development. Dr. Chawla will be raking in a salary of $450,000 per year and will be eligible to receive various bonuses in both cash and stock. However, the high price for the position doesn’t come without benefit. Dr. Chawla has a long history in the drug development space, and considering the status of aldoxorubicin, now is the perfect time to move him up. In a statement, Steven A Kriegsman, Chairman and CEO at CYTR, had the following to offer:




Dr. Shanta Chawla who is a Board certified physician has played a key role in the late-stage development and NDA submissions of several oncology drugs and has been involved in the day-to-day clinical development of aldoxorubicin for more than 3 years… Together with the rest of our clinical and regulatory team and external regulatory council, Dr. Margaret Hurley, a renowned development strategist, we remain well-equipped to execute on the regulatory strategy for aldoxorubicin.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

Is CytRx Gearing Up For An Acquisition?

Before I get into this topic, there is currently no news that CYTR is going to be acquired, not even a rumor hitting the wire. So, keep in mind that this is all speculation here. Nonetheless, if we dig into the details surrounding CYTR, it’s easy to see why this could be a perfect takeover target.

Think about it; CytRx is working on bringing its flagship candidate, aldoxorubicin, to the market. While this is still a while off, the recent Phase 3 clinical trial yielded exceptional results, showing that there is tremendous value in the treatment. At the moment, CYTR has a market cap of around 116.02 million. In the world of oncology, that’s pennies my friends.

If a competitor wanted to get an exceptional deal on the assets owned by CYTR, that competitor would have to move quickly. After all, if they wait until the next milestone, the stock could shoot up in value, leading to a larger price for anyone interested.

As a result, with a strong product that’s likely to get the nod from the FDA and a relatively minimal market cap, now would be the time for any interested suitors to pounce. So, I wouldn’t be surprised to see a takeover take place in the coming months!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CYTR. In particular, we’re interested in following the company’s ongoing efforts with regard to bringing aldoxorubicin to market and we’ll be waiting to see if any of the larger companies in the oncology space vie for a takeover. We’ll continue to follow the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 4879
Gilead Sciences Inc GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD) wasn’t off to the strongest of days in the market today, at least not early on. The stock took an early morning dive and has been in the red since. However, minutes ago, the stock started spiking toward the green as the result of a takeover rumor. Of course, our partners at Trade Ideas were the first to alert us to the movement. At the moment (10:01), GILD is trading at $64.41 per share after a loss of $0.41 per share (0.63%) thus far today.





GILD Gains On Takeover Rumors

As mentioned above, while Gilead Sciences hasn’t yet made it to the green, it is spiking upward as takeover rumors break. The rumors suggest that Sanofi (SNY) is interested in purchasing the company. However, the rumors are quite vague. There is no insinuation of what the price of the takeover might be, nor when it will happen.




It’s important to keep in mind that takeover rumors are nothing new to the market. In fact, we see them all the time. The truth is that very few of these rumors ever come to fruition. While there’s reason for SNY to be interested in taking GILD over, there is no confirmation from either side. So, if you’re going to trade on this news, be sure to do so with caution!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on GILD and SNY. While the rumor is vague, the takeover proposition does make sense. So, this one could go either way. We’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Youngevity International YGYID Stock News

Youngevity International Inc (OTCMKTS: YGYID) (NASDAQ: YGYI) is creating a bit of a compelling opportunity at the moment, and for good reason. The stock will uplist to the NASDAQ tomorrow, Wednesday, June 21st, 2017. However, that’s not the only bit of news the company has released as of yet. In fact, investors have seen a flurry of press releases, the most recent of which announced the Youngevity International’s largest acquisition to date. Today, we’ll talk about the NASDAQ uplist, the acquisition news, and what we’ll be watching for with regard to YGYID ahead.





YGYID To Become YGYI And List On The NASDAQ

As we know, Youngevity International is gearing up for an uplist. In fact, the stock will be traded on the NASDAQ tomorrow. This is incredible news as it will help to drive more value for shareholders. In a statement with regard to the uplist, Steve Wallach, Co-Founder and CEO at YGYID, had the following to offer




Youngevity’s listing on the NASDAQ Capital Market is a major corporate milestone and a source of great pride for the Youngevity family of employees, distributors, executives and supporters that have contributed to this moment. What enhances the sense of pride and accomplishment is that Youngevity attains this listing by executing and delivering on our business plan and our priority to grow shareholder value with minimal dilution. We are happy to say that meeting NASDAQ’s requirements is a culmination of the dedication and hard work of so many throughout the Youngevity family.”

Youngevity Announces Largest Acquisition To Date

As mentioned above, the fact that YGYID is uplisting to the NASDAQ tomorrow hasn’t stopped the company from releasing news. In fact, yesterday the company released big news surrounding an acquisition. Essentially, Youngevity has entered into a definitive agreement for the acquisition of Sorvana International. Sorvana is the result of a combination of 2 natural wellness companies known as FreeLife and L’dara. The closing of the transaction will take place on July 1st, 2017. In a statement, Steve Wallach, CEO and Co-Founder of YGYID, had the following to offer…

FreeLife has a proud 22 year history of success in the Direct Selling Profession and L’dara’s patented skin care products are very special. We believe acquiring Sorvana International represents a true expansion of our mission of betterment, and delivering exceptional, science based wellness products for optimal health to our customers… We are very proud of this acquisition as it represents our largest transaction in terms of top line revenue and in numbers of quality field leadership.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Moving Forward

Moving forward, the CNA Finance team will be keeping a close eye on YGYID. In particular, we’re interested in seeing just how the uplist to NASDAQ goes, following the revenue growth after the acquisition of Sorvana, keeping track of CLR Roasters, and much, much more. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1030
Neos Therapeutics Inc NEOS Stock News

Neos Therapeutics Inc (NASDAQ: NEOS) is having an incredibly strong start to the trading session today, and for good reason. The company is the center of attention, as today is a key PDUFA date for the company. Of course, this is leading to excitement and gains, prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:53), NEOS is trading at $9.12 per share after a gain of $0.47 per share (5.49%) thus far today.





NEOS PDUFA Date Is Today

As mentioned above, Neos Therapeutics is having a relatively strong morning in the market this morning as today is the PDUFA date for the company. Six months ago today, the company resubmitted the application for Cotempla XR-ODT, which is the brand name for methylphenidate extended-release orally disintegrating tablets. The treatment is designed to treat ADHD.




The application was first submitted in 2015. However, the FDA had a few concerns about the treatment. NEOS is confident that it has addressed those concerns and that Cotempla will be approved. There’s one thing we do know – we’re going to find out whether the treatment is approved or denied by the end of the day today.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NEOS. In particular, we’re interested in learning whether or not Cotempla will be approved by the FDA. Of course, if the drug is approved, the stock will likely fly, while a denial of marketing authorization will likely tank the stock. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5500
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...